Abdelsalam Mohamed Said, Rashwan Mohamed, Althaf Mohamed Mahdi, Alfurayh Osman I, Alkorbi Lutfi, Ibrahim Ihab A
Department of Medicine, Section of Nephrology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia; Department of Internal Medicine, Nephrology Unit, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Department of Medicine, Section of Nephrology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Saudi J Kidney Dis Transpl. 2018 Jan-Feb;29(1):107-113. doi: 10.4103/1319-2442.225191.
Conventional hemodialysis (HD) is the most common treatment modality used for renal replacement therapy. The concept of HD is based on the diffusion of solutes across a semipermeable membrane. Hemofiltration (HF) is based on convective transport of solutes; hemodiafiltration (HDF) is based on combined convective and diffusive therapies. Data about survival benefit of on-line HDF (OL-HDF) over high-flux HD (HF-HD) is conflicting. We conducted this study to investigate if there is a survival difference between the two treatment modalities. This study is a retrospective, single-center study in which 78 patients were screened; 18 were excluded and 60 patients were analyzed. The study patients were aged 47.5 ± 20.7 years, 33 patients (55%) were on HF-HD, and 27 patients (45%) were on OL-HDF. A total of 24 patients (40%) of both groups were diabetic and, the mean duration on dialysis was 43.5 ±21.3 months in the HF-HD group and 41.2 ± 22.0 months in the OL-HDF group. The mean substitution volume for OL-HDF was 22.3 ± 2.5 L. Survival was 73% [95%, confidence interval (CI) 60-84] in the HF-HD group and 65% (95%, CI 54-75) in the OL-HDF group by the end of the study period. The unadjusted hazard ratio (HR) with 95% CI comparing HF-HD to high-volume postdilution OL-HDF was 0.78 (0.10-5.6; P = 0.810). Kaplan-Meier analysis for patient survival over five years showed no significant difference between the two modalities. Prospective controlled trials with a larger number of patients will be needed to assess the long-term clinical outcome of postdilution OL-HDF over HF-HD.
传统血液透析(HD)是用于肾脏替代治疗最常见的治疗方式。血液透析的概念基于溶质通过半透膜的扩散。血液滤过(HF)基于溶质的对流运输;血液透析滤过(HDF)基于对流和扩散联合治疗。关于在线血液透析滤过(OL-HDF)相对于高通量血液透析(HF-HD)的生存获益数据存在冲突。我们开展这项研究以调查这两种治疗方式之间是否存在生存差异。本研究是一项回顾性单中心研究,筛选了78例患者;18例被排除,对60例患者进行了分析。研究患者年龄为47.5±20.7岁,33例患者(55%)接受HF-HD治疗,27例患者(45%)接受OL-HDF治疗。两组共有24例患者(40%)患有糖尿病,HF-HD组的平均透析时长为43.5±21.3个月,OL-HDF组为41.2±22.0个月。OL-HDF的平均置换量为22.3±2.5L。到研究期末,HF-HD组的生存率为73%[95%,置信区间(CI)60 - 84],OL-HDF组为65%(95%,CI 54 - 75)。比较HF-HD与高容量后置稀释OL-HDF的未调整风险比(HR)及95%CI为0.78(0.10 - 5.6;P = 0.810)。对患者五年生存情况的Kaplan-Meier分析显示,两种方式之间无显著差异。需要开展有更多患者参与的前瞻性对照试验,以评估后置稀释OL-HDF相对于HF-HD的长期临床结局。